prikaz prve stranice dokumenta Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity
  Download
PDF 642.34 KB
Scientific paper - Original scientific paper
Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity
Antibodies, 12 (2023), 2; 37. https://doi.org/10.3390/antib12020037
Premužić, Vedran; Stevanović, Ranko; Vilibić-Čavlek, Tatjana; Sirovica, Maja; Stalman, Sara; Bogdanić, Maja; Žilić, Denis; Nakić, Dario; Santini Dušević, Danijela; Vojković, Marina; Barbić, Jerko; Durlen, Ivan; Grđan, Željka; Pavlović, Draško; Kudumija, Boris; Sefer, Siniša; Griparić, Davor; Rogić, Dunja; Bubaš, Marija; Capak, Krunoslav; Jelaković, Bojan More authors...

Cite this document

Premužić, V., Stevanović, R., Vilibić Čavlek, T., Sirovica, M., Stalman, S., Bogdanić, M. ... Jelaković, B. (2023). Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity. Antibodies, 12. (2). doi: 10.3390/antib12020037

Premužić, Vedran, et al. "Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity." Antibodies, vol. 12, no. 2, 2023. https://doi.org/10.3390/antib12020037

Premužić, Vedran, Ranko Stevanović, Tatjana Vilibić Čavlek, Maja Sirovica, Sara Stalman, Maja Bogdanić, Denis Žilić, et al. "Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity." Antibodies 12, no. 2 (2023). https://doi.org/10.3390/antib12020037

Premužić, V., et al. (2023) 'Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity', Antibodies, 12(2). doi: 10.3390/antib12020037

Premužić V, Stevanović R, Vilibić Čavlek T, Sirovica M, Stalman S, Bogdanić M, and sur.. Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity. Antibodies [Internet]. 2023 May 24 [cited 2024 October 13];12(2). doi: 10.3390/antib12020037

V. Premužić, et al., "Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity", Antibodies, vol. 12, no. 2, May 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:513281. [Accessed: 13 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity
AuthorVedran Premužić
AuthorRanko Stevanović
AuthorTatjana Vilibić-Čavlek
AuthorMaja Sirovica
AuthorSara Stalman
AuthorMaja Bogdanić
AuthorDenis Žilić
AuthorDario Nakić
AuthorDanijela Santini Dušević
AuthorMarina Vojković
AuthorJerko Barbić
AuthorIvan Durlen
AuthorŽeljka Grđan
AuthorDraško Pavlović
AuthorBoris Kudumija
AuthorSiniša Sefer
AuthorDavor Griparić
AuthorDunja Rogić
AuthorMarija Bubaš
AuthorKrunoslav Capak
AuthorBojan Jelaković
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Medical Microbiology and Parasitology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Medical Microbiology
Abstract (english)
Background: The effectiveness of the COVID-19 vaccine may differ in hemodialysis patients. The aim of this prospective multicenter study was to determine the degree of serological response to the SARS-CoV-2 vaccine in the population of dialysis patients and its association with later SARS-CoV-2 infections. Methods: A blood sample was taken for the determination of COVID-19 serological status (IgG antibodies) in 706 dialysis patients 16 weeks after vaccination with the second dose (Pfizer-BioNTech). Results: Only 314 (44.5%) hemodialyzed patients had a satisfactory response to the COVID-19 vaccine. Eighty-two patients (11.6%) had a borderline response, while 310 patients (43.9%) had an unsatisfactory (negative) post-vaccinal antibody titer. A longer dialysis vintage had an increased odds ratio (OR) of 1.01 for the occurrence of COVID-19 positivity after vaccination. In the group of subsequently positive patients, 28 patients (13.6%) died from complications of COVID-19. We have found differences in mean survival time between patients with and without appropriate responses to vaccination in favor of patients with a satisfactory serological response. Conclusions: The results showed that the dialysis population will not have the same serological response to the vaccine as the general population. The majority of dialysis patients did not develop a severe clinical picture or die at the time of positivity for COVID-19.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleAntibodies
Numberingvol. 12, no. 2, 37
e-ISSN2073-4468
DOIhttps://doi.org/10.3390/antib12020037
URN:NBNurn:nbn:hr:105:513281
Publication2023-05-24
Document URLhttps://www.mdpi.com/2073-4468/12/2/37
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-09-25 08:34:36